ECSP19072975A - Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos - Google Patents

Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos

Info

Publication number
ECSP19072975A
ECSP19072975A ECSENADI201972975A ECDI201972975A ECSP19072975A EC SP19072975 A ECSP19072975 A EC SP19072975A EC SENADI201972975 A ECSENADI201972975 A EC SENADI201972975A EC DI201972975 A ECDI201972975 A EC DI201972975A EC SP19072975 A ECSP19072975 A EC SP19072975A
Authority
EC
Ecuador
Prior art keywords
compounds
pyrimidine derivatives
pyrazole
allicyclics
pharmacologically active
Prior art date
Application number
ECSENADI201972975A
Other languages
English (en)
Spanish (es)
Inventor
István Borza
Viktor Román
Zsuzsa Hadady
János Éles
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of ECSP19072975A publication Critical patent/ECSP19072975A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ECSENADI201972975A 2017-03-13 2019-10-10 Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos ECSP19072975A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
ECSP19072975A true ECSP19072975A (es) 2019-11-30

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201972975A ECSP19072975A (es) 2017-03-13 2019-10-10 Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos

Country Status (32)

Country Link
US (1) US11026946B2 (enExample)
EP (1) EP3596080B1 (enExample)
JP (1) JP7153662B2 (enExample)
KR (1) KR20190127779A (enExample)
CN (1) CN110431142A (enExample)
AR (1) AR111176A1 (enExample)
AU (1) AU2018235266B2 (enExample)
BR (1) BR112019018843A2 (enExample)
CA (1) CA3056185A1 (enExample)
CL (1) CL2019002601A1 (enExample)
CO (1) CO2019010120A2 (enExample)
CY (1) CY1124708T1 (enExample)
DK (1) DK3596080T3 (enExample)
EA (1) EA038756B1 (enExample)
EC (1) ECSP19072975A (enExample)
ES (1) ES2893824T3 (enExample)
GE (1) GEP20217256B (enExample)
HR (1) HRP20211850T1 (enExample)
HU (2) HU231058B1 (enExample)
IL (1) IL268923A (enExample)
LT (1) LT3596080T (enExample)
MX (1) MX2019011000A (enExample)
MY (1) MY195262A (enExample)
PE (1) PE20191646A1 (enExample)
PH (1) PH12019501968A1 (enExample)
PL (1) PL3596080T3 (enExample)
PT (1) PT3596080T (enExample)
RS (1) RS62533B1 (enExample)
SG (1) SG11201907864YA (enExample)
SI (1) SI3596080T1 (enExample)
UA (1) UA124783C2 (enExample)
WO (1) WO2018167630A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2021239558A1 (en) 2020-05-27 2021-12-02 Esteve Pharmaceuticals, S.A. Pyrazolo[1,5-a]pyrimidine derivatives having multimodal activity against pain
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508310A (pt) 2004-03-02 2007-07-24 Hoffmann La Roche derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR100753017B1 (ko) * 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-a]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
WO2009123986A1 (en) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
WO2016169995A1 (en) * 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Also Published As

Publication number Publication date
PE20191646A1 (es) 2019-11-07
HUP1700108A2 (en) 2018-09-28
US11026946B2 (en) 2021-06-08
IL268923A (en) 2019-10-31
CY1124708T1 (el) 2022-07-22
AR111176A1 (es) 2019-06-12
BR112019018843A2 (pt) 2020-04-14
AU2018235266B2 (en) 2021-09-30
EP3596080B1 (en) 2021-09-01
HRP20211850T1 (hr) 2022-03-04
GEP20217256B (en) 2021-05-25
JP2020510041A (ja) 2020-04-02
HUE056562T2 (hu) 2022-02-28
PL3596080T3 (pl) 2022-01-31
JP7153662B2 (ja) 2022-10-14
SG11201907864YA (en) 2019-09-27
RS62533B1 (sr) 2021-11-30
ES2893824T3 (es) 2022-02-10
AU2018235266A1 (en) 2019-10-17
CN110431142A (zh) 2019-11-08
MX2019011000A (es) 2019-10-17
CO2019010120A2 (es) 2019-10-09
UA124783C2 (uk) 2021-11-17
WO2018167630A1 (en) 2018-09-20
HU231058B1 (hu) 2020-04-28
US20200129515A1 (en) 2020-04-30
SI3596080T1 (sl) 2022-01-31
EP3596080A1 (en) 2020-01-22
DK3596080T3 (da) 2021-11-15
EA201992127A1 (ru) 2020-02-06
CL2019002601A1 (es) 2020-01-24
KR20190127779A (ko) 2019-11-13
MY195262A (en) 2023-01-11
LT3596080T (lt) 2021-11-25
PT3596080T (pt) 2021-10-22
PH12019501968A1 (en) 2020-06-29
EA038756B1 (ru) 2021-10-14
CA3056185A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
CO2019010120A2 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
DOP2021000070A (es) Inhibidores de la proteína tirosina fosfatasa
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CO2020005459A2 (es) Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
CO2019004065A2 (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
MX2019006637A (es) Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
UY38093A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
CL2023000352A1 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos
UY36573A (es) Compuestos bicíclicos de sulfonamida cetona
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
CL2020001140A1 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x.
MX387232B (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2021002093A1 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x.
CL2021000080A1 (es) Derivados de espirocromano
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
CO2024003953A2 (es) Derivados de benzodiazepina como moduladores alostéricos positivos del receptor de gaba a gamma1
CL2025000272A1 (es) Derivados de arilo tricíclico y composiciones y métodos de los mismos
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
AR127170A1 (es) Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos
MX2022001023A (es) Compuestos de aminotiolester y usos de los mismos.
ES3063880T3 (en) Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-ht4 receptor agonists